Pharmacy Times

JULY 2, 2025

Common adverse reactions included gastrointestinal issues, with a low discontinuation rate due to adverse drug reactions. OLC, a lanthanum-based phosphate binder, showed efficacy and tolerability in a phase 2 trial, with most patients achieving target serum phosphate levels.

Pharmacy Technician 29

Pharmacy Technician Compounding Pharmacies Pharmacy Management Adverse Reactions 29

Pharmacy Times

JUNE 12, 2025

3 The safety profile was favorable with the most common adverse effect (AE) being increased creatinine, increased potassium, dysuria, decreased hemoglobin, increased aspartate aminotransferase, increased alanine aminotransferase, increased eosinophils, decreased lymphocytes, urinary tract infection, decreased neutrophils, and hematuria.

Pharmacy Technician 26

Pharmacy Technician Compounding Pharmacies Biosimilars Pharmacy Management 26

Pharmacy Times

JULY 9, 2025

While no new adverse reactions were observed in this study, higher rates of hypersensitivity and infusion-related reactions were observed.

Labelling 26

Labelling Pharmacy Technician Compounding Pharmacies Independent Pharmacies 26

pharmaphorum

NOVEMBER 4, 2020

Grade 3–4 adverse events occurred in 57% of people receiving Tecentriq and Avastin and 55% of people receiving sorafenib. The most frequent serious adverse reactions for the combination, occurring in 2% or more of patients, were bleeding in the gastrointestinal tract and fever.

Adverse Reactions 64

Adverse Reactions Biosimilars Immunity Immunization 64

RX Note

FEBRUARY 23, 2023

Drug-Food Interactions - Predominantly the effect of food on absorption Drugs and Pregnancy - Discussing FDA Pregnancy and Lactation Final Rule and Australian Categories for Prescribing Medicines in Pregnancy Drugs and Lactation - Discussing key references Dosing in Obese - One dose fits all?

HIV Treatment and Prevention Agents 58

HIV Treatment and Prevention Agents Community Pharmacies Labelling Chemotherapy 58